Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...
VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...